Anti-VEGF antibody therapy for psoriasis?

Anti-Gliadin antibody in Psoriasis: A case-control study

Background and objective: Psoriasis is chronic inflammatory skin disorder with a wide variety of clinical presentations. Presence of anti-gliadin antibody (AGA) has been reported in 16% of psoriatic patients. This study was designed to determine the frequency of the presence of AGA in psoriatic patients. Materials and Methods: After recording the demographic data and the severity of disease acc...

ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA Anti-VEGF Therapy For Diabetic Macular Edema

Pazopanib and anti-VEGF therapy

Pazopanib (Votrient™, GlaxoSmithKline), a multi-kinase inhibitor with activity against VEGFR and other receptors, was recently approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). Here, we review the history of its development, together with an overview of VEGF and its receptors and co-receptors. Results from selected clinical trial data in RCC and other malignant disea...

VEGF involvement in psoriasis

Vascular endothelial growth factor (VEGF) is a key growth factor, regulating the neovascularization, during embryogenesis, skeletal growth, reproductive functions and pathological processes. The VEGF receptors (VEGFR) are present in endothelial cells and other cell types, such as vascular smooth muscle cells, hematopoietic stem cells, monocytes, neurons, macrophages, and platelets. Angiogenesis...

Tumor refractoriness to anti-VEGF therapy

Vascular endothelial growth factor (VEGF) has been identified as the most potent cytokine involved in tumor angiogenesis and metastasis formation. Clinical results of anti-angiogenic therapies targeting VEGF and its receptors are very modest, resulting in a moderate improvement of overall survival. The clinical outcome is associated with the development of resistance and the increased risk of i...